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Increased oxidative stress is indisputably an important 
mechanism of doxorubicin side effects, especially its 
cardiotoxicity. To prevent impairment of non-tumorous tissue and 
to improve the specificity in targeting the tumor tissue, new drug 
nanotransporters are developed. In many cases preclinical 
therapeutic advantage has been shown when compared with the 
administration of conventional drug solution. Three forms of 
doxorubicin – conventional (DOX), encapsulated in liposomes 
(lipoDOX) and in apoferritin (apoDOX) were applied to Wistar 
rats. After 24 h exposition, the plasma level of 4-hydroxy-2-
nonenal (4-HNE) as a marker of lipoperoxidation and tissue gene 
expression of thioredoxin reductase 2 (TXNRD2) and aldehyde 
dehydrogenase 3A1 (ALDH3A1) as an important part of 
antioxidative system were determined. Only conventional DOX 
significantly increases the level of 4-HNE; encapsulated forms on 
the other hand show significant decrease in plasma levels of 
4-HNE in comparison with DOX. They also cause significant 
decrease in gene expression of ALDH3A1 and TXNRD2 in liver as 
a main detoxification organ, and a mild influence on the 
expression of these enzymes in left heart ventricle as a potential 
target of toxicity. Thus, 4-HNE seems to be a good potential 
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Anthracycline doxorubicin (DOX) is one of the 
most frequently used antitumor drugs, with high activity 
against an extensive variety of malignancies, both 
hematological and solid tumors – gynecological, 
urogenital, endocrine, stomach cancer, as well as Ewing 
and Kaposi’s sarcomas (reviewed by Carvalho et al. 
2009). 
Numerous side effects which limit the wider 
application of doxorubicin were reported, including 
nausea, vomiting and fever (reviewed by Carvalho et al. 
2014). Moreover, significant incidence of acute and 
chronic cardiovascular side effects that may even 
endanger the patient's life were also observed (Singal and 
Iliskovic 1998). In general, acute DOX side effects are 
reversible and well treatable. Nevertheless, when the 
lifetime cumulative DOX dose is nearing 500 mg/m2 and 
above this value, iatrogenic life-threatening 
cardiomyopathy becomes more probable; it can even 
develop into dilated cardiomyopathy and eventually to 
congestive heart failure (Chatterjee et al. 2010, Shi et al. 
2011). 
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However, despite a significant research effort, 
the mechanism of DOX chronic cardiotoxicity is not fully 
clarified even after years of its clinical application. 
Suggested pathways responsible for its cardiotoxicity 
include inactivation of key enzymes, suppression of 
DNA, RNA and protein synthesis, abnormalities in Ca2+ 
handling, and above all oxygen free radical formation and 
iron oxidation (Sawyer et al. 2010). High level of 
oxidative stress generated by DOX treatment is related 
with its molecular structure, which contains quinone 
moiety able to undergo a redox cycling producing 
superoxide anion radical O2∙− (Millic Torres and 
Dragojevic Simic 2012). In a presence of metal ions, 
especially iron, highly toxic hydroxyl radical (OH∙) is 
generated from O2∙−. OH∙ is extremely toxic and can’t be 
detoxified by any antioxidative enzyme. It reacts besides 
other substrates willingly with polyunsaturated fatty acids 
of lipid membranes and impairs them by lipid 
peroxidation. This chain of reactions leads to a high level 
of secondary peroxidation products, such as acrolein, 
malondialdehyde, 4-hydroxy-2-nonenal (4-HNE) and 
many other aldehydes. 4-HNE is considered to be highly 
reactive and cytotoxic with potential to damage all major 
types of macromolecules. There is a variety of defensive 
mechanisms for antioxidant protection in the cells, for 
example superoxide dismutase for converting O2∙− to less 
harmful hydrogen peroxide. Among the other defense 
mechanisms, an important role is seen in the aldehyde 
dehydrogenase (ALDH), which metabolizes toxic 
aldehydes originating from lipid peroxidation. Last but 
not least there are also thiol-dependent systems. These are 
critical for cellular redox environment control by 
maintaining dithiol/disulfide balance of numerous 
proteins involved in essential cell functions (Lu and 
Holmgren 2014). Thioredoxin belongs to these systems 
and thioredoxin reductase (TXNRD) plays an important 
role in cellular defensive system. 
Cancer chemotherapy is generally limited by 
a lack of specificity in the targeting to tumor tissue. 
Accordingly, reduction of the side effects on non-
tumorous tissue is one of the major challenges in 
oncology. One of the approaches to overcome such 
limitations is encapsulation of conventional drugs. 
Encapsulation of DOX into the nanomaterial carrier 
decreases the toxic effect caused by this cytostatic drug 
and protects healthy tissues. It also improves tumor 
targeting via the enhanced permeation and retention 
effect which has been demonstrated for a range of 
nanosized drug delivery systems. Besides liposomal 
nanocarriers, which were recently introduced into clinical 
practice, transporters based on protein (apo)ferritin (Todd 
et al. 2013) and/or carriers utilizing carbon 
nanomaterials, such as fullerenes or carbon nanotubes 
(Wong et al. 2013) are intensively studied. 
The aim of the study was to verify whether  
4-HNE is good potential biomarker of oxidative stress 
and apply it for comparison of the effects of conventional 
doxorubicin and its two encapsulated forms (liposomal 
DOX anSd DOX in apoferritin transporter) on the level of 
oxidative stress in rat, using 4-HNE as a marker of 
lipoperoxidation and two selected lipoperoxidation-
related genes – aldehyde dehydrogenase 3A1 (ALDH3A1) 
and thioredoxin reductase 2 (TXNRD2). 
 
Materials and Methods 
 
Materials 
All chemicals used in biochemical analyses were 
of the p.a. or HPLC grade, purchased from Sigma-
Aldrich (St. Louis, MO, USA). Standard of 4-HNE was 
purchased from Cayman Chemical (Ann Arbor, MI, 
USA). Kits used for RNA isolation and PCR reaction 
were manufactured by Roche (Basil, Switzerland). 
All doxorubicin compounds were kindly 
provided by Laboratory of Metallomics and 
Nanotechnologies, Department of Chemistry and 
Biochemistry, Faculty of Agronomy, Mendel University, 
Brno, Czech Republic. The applied forms of doxorubicin 
were as follows: conventional doxorubicin – DOX (Teva 
2 mg/ml powder for infusion solution), doxorubicin 
encapsulated in apoferritin transporter – apoDOX 
(characterized in Gumulec et al. 2014), and liposomal 
doxorubicin – lipoDOX (DOX encapsulated in liposome 
10, characterized in Kominkova et al. 2014). 
 
Experimental animals 
All experiments were carried out according to 
the recommendations of the European Community Guide 
for the Care and Use of Laboratory Animals and 
according to the experimental protocol approved by the 
local Committee on the Protection of Animals, Masaryk 
University and by the Committee of Ministry of 
Agriculture of the Czech Republic. Animals were housed 
in the Animal Breeding and Experimental Facility, 
Faculty of Medicine, Masaryk University, Brno, Czech 
Republic in temperature, pressure and humidity 
controlled environment, with light cycle 12/12 light/dark. 
In the study, 30 male Wistar rats (body mass 
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302.2±9.3 g) were used. Animals were divided into four 
groups: group A, n=8, 306.4±17.2 g; group B, n=7, 
302.9±26.1 g; group C, n=8, 293.4±18.4 g; and group D, 
n=7, 306.7±15.0 g. Three days before drug exposure, 
animals were housed individually in glass metabolic 
cages (Simax, Czech Republic) for adaptation. After 
adaptation period, DOX (5 mg/kg), apoDOX (equal to 
5 mg/kg of DOX), and lipoDOX (equal to 5 mg/kg of 
DOX), were applied by single intraperitoneal injection in 
light inhalation anesthesia (group B, C, and D, 
respectively). To group A, which served as a negative 
control, vehiculum – aqua pro injectione (2.78 ml/kg) 
was applied. 
Twenty four hours after application, animals 
were deeply anesthetized (Ketamine 100 mg/kg i.p. and 
Xylazine 10 mg/kg i.p.), thoracotomy was performed, 
blood samples were collected into the syringe with EDTA 
by direct intracardial puncture and the heart was excised. 
Samples from heart, liver, kidney and testes were 
promptly obtained, immediately frozen in liquid nitrogen 
and stored at −80 °C for further analyses. 
 
Biochemical analysis 
The level of 4-HNE was measured by modified 
method according to Kinter (1996). Plasma samples were 
obtained from blood with EDTA and stored at −80 °C 
until assayed. Preparation of sample included the addition 
of butylated hydroxytoluene to avoid artificial oxidation 
and deproteination by perchloric acid with subsequent 
centrifugation. Then 2,4-dinitrophenylhydrazine as 
a derivatization reagent was mixed with aliquot of 
supernatant and incubated for 1 h in dark place and then 
the product was extracted to hexane. Sample was 
evaporated to dryness under nitrogen and redissolved in 
60 % acetonitrile. The amount of the product was 
measured by HPLC with UV detection. Conditions 
applied for measurement were as follows: column 
Kinetex C-18 (100 mm × 4.6 mm, 5 µm), acetonitrile 
mobile phase (55:45, v/v), isocratic conditions with flow 
rate 0.5 ml/min, UV detector (LCD 2084.2, ECOM, CZ) 
set at 355 nm and software for analysis ClarityTM 
(DataApex, CZ). The plasma 4-HNE concentration was 
calculated according to the standard curve. 
 
RNA isolation and reverse transcription 
High pure total RNA isolation kit was used for 
isolation. The medium was removed and the samples 
were twice washed with 5 ml of ice-cold PBS. The cells 
were scraped off, transferred to clean tubes and 
centrifuged at 20,800 × g for 5 min at 4 °C. After this 
step, a lysis buffer was added and RNA isolation was 
carried out according to manufacturer’s instructions. The 
isolated RNA was used for cDNA synthesis. RNA 
(600 ng) was transcribed using transcriptor first strand 
cDNA synthesis kit, which was applied according to 
manufacturer’s instructions. The cDNA (20 μl) prepared 
from the total RNA was diluted with RNase free water to 
100 μl and the amount of 5 μl was directly analyzed by 
using the Lightcycler 480 II RT-PCR system (Roche, 
Basel, Switzerland). 
 
Quantitative real-time polymerase chain reaction 
q-PCR was performed in triplicate using the 
TaqMan gene expression assay system with the 
Lightcycler 480 II RT-PCR system; the amplified DNA 
was analyzed by the comparative Ct method using β-actin 
(ACTB) as an endogenous control for ALDH3A1 and 
TXNRD2 gene expression quantification. The primer and 
probe sets for ACTB (assay ID: Rn00667869_m1), 
ALDH3A1 (Rn00694669_m1), and TXNRD2 
(Rn00574868_m1), were selected from TaqMan gene 
expression assays (Life Technologies, Waltham, MA, 
USA). q-PCR was performed under the following 
amplification conditions: total volume of 20 μl, initial 
incubation at 50 °C/2 min, followed by denaturation at 
95 °C/10 min, then 45 cycles at 95 °C/15 s and at 
60 °C/1 min. 
 
Statistical analysis 
One-way ANOVA followed by planned 
comparisons (contrast analysis) was used to reveal 
dependencies between variables. Data were tested for 
normality and log-normal data were transformed 
accordingly. Unless noted otherwise, P level <0.05 was 
considered significant. Software Statistica 12 (StatSoft, 




Effect of DOX forms on plasma level of 4-HNE 
First, the effect of doxorubicin modification on 
the plasma level of 4-HNE was analyzed using univariate 
analysis. There was a significant effect on the plasma 
level of this metabolite, F(3,26)=34.85, p<0.001. To 
reveal differences between individual forms of 
doxorubicin modifications and negative control, planned 
comparisons (contrast analysis) was performed. The 
plasma concentration of 4-HNE was significantly 
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(4.35-fold) higher when treated with conventional DOX 
as compared to negative control (p<0.001). In the next 
step, novel doxorubicin modifications (lipoDOX and 
apoDOX) were compared to conventional DOX. The 
plasma 4-HNE level was significantly (2.41-fold) lower 
after exposure to those novel forms as compared to 
conventional DOX, p<0.001. Additionally, although the 
plasma 4-HNE level was 1.46-fold lower after apoDOX 
treatment as compared to lipoDOX, no significance was 





Fig. 1. Plasma level of 4-hydroxy-2-nonenal after 24 h exposure 
to various doxorubicin modifications. Asterisks indicate 
a significant difference at p<0.05. Displayed as median, box plots 




Effect on gene expression 
Next, the mRNA expression level of TXNRD2 
and ALDH3A1 was analyzed in two tissues – liver and 
left ventricle. Multivariate testing revealed that the effect 
of DOX treatment on the expression of these genes was 
significant in both liver tissue F(9,58)=7.53, p<0.001 and 
left ventricular tissue, F(9,48)=4.02, p<0.001. As 
apparent from Figure 2, the trend of these genes after the 
treatment with negative control, conventional 
doxorubicin and novel forms is similar as the trend of 
4-HNE (compare Fig. 1 and Fig. 2). With regard to the 
liver tissue, highest expression of ALDH3A1 and 
TXNRD2 was observed after conventional DOX 
treatment, as compared to novel forms of DOX 
modifications, p=0.03 and 0.01 for ALDH3A1 and 
TXNRD2, respectively. Although the gene expression of 
these genes after DOX treatment was higher as compared 
to negative control, the trend was below the significance 
level. Additionally, no significant difference in gene 
expression after application of apoDOX and lipoDOX 
was observed in liver tissue. 
With regard to the left ventricle, similar gene 
expression pattern was observed in ALDH3A1 gene. 





Doxorubicin-induced cardiotoxicity is 
a threatening side effect of oncological treatment. Acute 
toxicity occurs in approximately 11 % of patients and 
comprises pericarditis-myocarditis and arrhythmias, but 
is quite well treatable and preventable by various drug 
administrations. Chronic cardiomyopathy, on the other 
hand, is the most serious drawback of clinical use of 
anthracyclines. It can arise in 20 % of patients and 
usually has a clinical picture of dilated cardiomyopathy 
and congestive heart failure. The mortality of these 
patients reaches 50 %, increasing significantly with 
increasing cumulative DOX doses (Chatterjee et al. 
2010). The induction of generation of free radicals and 
initiation of oxidative stress is a known mechanism 
through which DOX causes cellular injury (Injac and 
Strukelj 2008) that can participate in the development of 
cardiotoxicity. 
In this study, we focused on applicability of 
4-HNE in plasma as a marker of oxidative stress after 
administration of various forms of DOX because 4-HNE 
is highly reactive secondary product of lipid peroxidation. 
It derives from ω-6 polyunsaturated fatty acids, which 
are, apart from others, important component of 
cardiolipin – relatively cardiospecific phospholipid of the 
inner mitochondrial membrane. Besides its role as 
a modulator of cell function (Leonarduzzi et al. 2000), 
the involvement of 4-HNE in pathogenesis of cardiac 
disorders such as atherosclerosis, hypertrophy or 
arrhythmias was reported (Mali and Palaniyandi 2014). In 
our animal model, significantly elevated plasma 4-HNE 
level was found after DOX treatment (4.35 fold higher 
when compared to negative control) that reflects an 
increase of oxidative stress. Elevated plasma level of 
4-HNE associated with various pathologies was also 
found in clinical studies (Mali and Palaniyandi 2014, 
Riahi et al. 2010). In order to counteract the adverse 
effects of 4-HNE and another lipid peroxidation-derived 
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aldehydes, many specific cellular defense mechanisms 
employing aldehyde dehydrogenases have been 
developed. They differ in cellular location and specificity 
to various aldehydes. Therefore, this study pointed on 
ALDH3A1 which efficiently metabolizes 4-HNE (Black 
et al. 2012, Singh et al. 2013). Oxidative stress also 
causes collapse of the mitochondrial membrane potential 
leading to impairment of oxidative phosphorylation of 
ADP (Gunter et al. 1994). It also induces nonspecific 
permeabilization of inner mitochondrial membrane 
(Kowaltowski et al. 1998). With this regard, inner 
mitochondrial membrane is suspected of releasing of the 
mitochondrial constituents, including cytochrome c, into 
cytosol, and therefore inducing apoptosis (Green and 
Reed 1998). Accordingly, apoptosis is predominant form 
of cardiomyocyte cell death triggered by cytostatic drugs, 
and both the extrinsic and intrinsic apoptotic pathways 






Fig. 2. Gene expression levels of TXNRD2 and ALDH3A1 after 24 h exposure to various doxorubicin modifications in liver and left 
ventricle. Asterisks indicate a significant difference at p<0.05. Displayed as median, box plots indicate 25-75 %, whiskers indicate non-
outlier range of variables. 
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The line of cell antioxidant protection provided 
by thioredoxin reductase 2 (TXNRD2) as a part of 
thioredoxin antioxidant system, has apparently essential 
role. Therefore, apart from 4-HNE detection, an 
expression of these two antioxidant defense-related genes 
– ALDH3A1 and TXNRD2 – in two relevant tissues (liver 
and left ventricle) was analyzed in this study. Our results 
in multivariate testing show significant effect of 
DOX-treatment on the expression of both enzymes in 
liver and left ventricle and also a similar trend as 
compared to 4-HNE. 
The importance of new drug formulations and 
their role in suppression of side effect of cancer treatment 
is high. Studies pursuing by new drug delivery systems 
have provided some evidence of the benefits resulting 
from their physical-chemical properties (Chau et al. 2006, 
van Vlerken et al. 2008). Only a few advanced delivery 
systems of DOX have been transferred into the clinical 
use – PEGylated and non-PEGylated liposomal 
nanocarrier of doxorubicin (Doxil® and Myocet®). 
Nowadays the research continues to find effective 
transporters, both liposomal and others, with beneficial 
functions and some of them are already in clinical studies 
(Perche and Torchilin 2013). We followed this trend by 
testing new nanotransporters – liposomal form without 
cholesterol, which shows better releasing of doxorubicin 
from liposomal particle (Kominkova et al. 2014) and 
apoferritin, the advantage of which is its potential to 
release its content in low pH environment, which is 
typical for tumor tissue (Gumulec et al. 2014). Our 
results support the idea of new transporters’ benefits by 
showing significantly decreased level of 4-HNE in 
plasma and gene expression of ALDH3A1 and TXNRD2 
in liver tissue as a main metabolizing organ after 
application of encapsulated forms of DOX in comparison 
with conventional DOX. Although this significant effect 
was not proved in left ventricle, the mild analogous trend 
was observed for ALDH3A1. It could be due to the fact 
that heart has low levels of some oxidative enzymes when 
compared with liver. Moreover, cardiomyocytes have 
a unique structure, in which 40 % of the organelles are 
mitochondria. Both these facts may explain why DOX is 
so toxic to heart (Ascensão et al. 2005). Taken together, 
our results show that plasma 4-HNE level sensitively 
reflects the changes of oxidative stress involved in the 
formation of cardiotoxicity after administration of 
different DOX formulations. 
In summary, an association between doxorubicin 
form and the severity of oxidative stress was proven. 
Encapsulated forms (lipoDOX and apoDOX) show 
significantly lower level of lipoperoxidation marker 
4-HNE in plasma. Gene expression of antioxidative 
enzymes thioredoxin reductase 2 and aldehyde 
dehydrogenase 3A1 was lower in liver tissue as a main 
detoxification organ after encapsulated form’s 
administration, too. On the other hand, there was very 
mild difference in gene expression of ALDH3A1 in the 
left ventricle as a main site of toxicity. It may be 
concluded that 4-HNE seems to be a good potential 
biomarker of doxorubicin-induced oxidative stress. 
Although this study brought certain interesting 
findings, some other issues remain unclear. Thus, further 
research is planned, investigating wider range of 
parameters describing oxidative stress in the same model. 
Moreover, comparison of rat and human models of 
oxidative stress induced by DOX treatment might be 
interesting. 
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